Figures & data
Figure 1 Patient at baseline (A–D) and after 4 weeks (E–H) of treatment with tildrakizumab.
Clinical, Cosmetic and Investigational Dermatology
Volume 16, 2023 - Issue
CASE REPORT
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
Luca PotestioSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
https://orcid.org/0000-0001-5940-0592View further author information
https://orcid.org/0000-0001-5940-0592View further author information, , , Fabrizio MartoraSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italyhttps://orcid.org/0000-0003-2523-050XView further author information
https://orcid.org/0000-0003-2523-050XView further author information, Angelo RuggieroSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyCorrespondence[email protected]
https://orcid.org/0000-0002-4658-7391View further author information
https://orcid.org/0000-0002-4658-7391View further author information &